STOCK TITAN

Palisade Bio Inc - PALI STOCK NEWS

Welcome to our dedicated news page for Palisade Bio (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Palisade Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Palisade Bio's position in the market.

Rhea-AI Summary
Palisade Bio, Inc. announced an agreement to exercise existing warrants, resulting in gross proceeds of approximately $2.5 million prior to deducting placement agent fees and estimated offering expenses. The company will issue new unregistered warrants to purchase shares of common stock in a private placement. The net proceeds from the offering will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.42%
Tags
none
-
Rhea-AI Summary
Palisade Bio, Inc. presented positive preclinical data of its lead asset, PALI-2108, at the Crohn’s & Colitis Congress. The preclinical data showed that PALI-2108 is safe and well-tolerated, orally delivered, and colon-activated, with low systemic exposure. The company is advancing PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) towards a Phase 1 clinical study expected to commence in 2024. The preclinical studies demonstrated that PALI-2108 offers localized bioactivation, colon-specific distribution, similar target engagement to other PDE4 inhibitors, dose-dependent efficacy in a mouse UC model, and no systemic toxicity in dogs, with a large therapeutic window due to local activation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
84.62%
Tags
-
Rhea-AI Summary
Palisade Bio, Inc. (Nasdaq: PALI) announced that its abstract has been accepted for poster presentation at the Crohn’s & Colitis Congress. The poster presentation, titled 'Local Bioactivation and Efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment', will take place on January 26, 2024, in Las Vegas, NV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
none
Rhea-AI Summary
Palisade Bio, Inc. (Nasdaq: PALI) receives second milestone payment for co-development partner Giiant Pharma, Inc. from the US Crohn’s and Colitis Foundation for the treatment of moderate-to-severe ulcerative colitis (UC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
-
Rhea-AI Summary
Palisade Bio, Inc. (Nasdaq: PALI) reported its financial results and business outlook, including a transformative transaction for the development of novel therapeutics for inflammatory bowel disease (IBD). The lead program, PALI-2108, an oral prodrug therapy for moderate-to-severe ulcerative colitis, is set to begin Phase 1 clinical study in 2024. The company has a strong financial position to achieve significant milestones into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
-
Rhea-AI Summary
Palisade Bio CEO to participate in Virtual Investor Ask the CEO Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
conferences
Rhea-AI Summary
Palisade Bio, Inc. has closed its registered direct offering, raising $1,965,094.32 in gross proceeds. The company plans to use the net proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.48%
Tags
-
Rhea-AI Summary
Palisade Bio appoints Mitchell Jones, M.D., Ph.D. as Chief Medical Officer. Dr. Jones has a proven track record in developing GI therapeutics. Palisade Bio aims to offer new treatment options for IBD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.95%
Tags
management
-
Rhea-AI Summary
Palisade Bio, Inc. announces definitive agreements for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32 in a registered direct offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.83%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
108.7%
Tags
none
Palisade Bio Inc

Nasdaq:PALI

PALI Rankings

PALI Stock Data

3.51M
836.48k
1.75%
15.52%
0.21%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Germantown